Blood
Articles in this Issue
DNMT1-mediated epigenetic regulation of heterochromatin in cellular aging
Abstract Background: Epigenetic remodeling is a hallmark of aging hematopoietic stem and progenitor cells (HSPCs). Loss of DNA methylation a...
Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study
Abstract Introduction Despite therapeutic advances in multiple myeloma (MM) treatment, managing heavily pretreated relap...
Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial.
Abstract Introduction CD19-directed chimeric antigen receptor T-cell therapy (CAR T) has significantly improved outcomes in relapsed/refract...
Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms
Abstract Introduction and Rationale Philadelphia-chromosome negative (Ph-) myeloproliferative neoplasms (MPNs) are hematopoietic stem cell d...
Targeting SF3B1 disrupts CLL cell survival via pfkfb-mediated glycolytic dependency and confers vulnerability to BTK inhibition
Abstract Background Chronic lymphocytic leukemia (CLL), the most prevalent form of adult leukemia, remains a challenge in terms of optimal t...
The efficacy and immunological differences of anti-t lymphocyte globulin and anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation
Abstract Objective To analyze the efficacy and immunological differences of anti-T-lymphocyte globulin ( ATLG ) and anti-thymocyte globulin...
IL-17–Induced CD70 expression promotes T-cell suppression in DLBCL: Implications for immune escape and T-cell exhaustion
Abstract Background: Diffuse Large B-cell Lymphoma (DLBCL) is one of the most aggressive types of non-Hodgkin B-cell lymphomas, characterize...
The role of G0S2 in FLT3+ AML bone marrow microenvironment and metabolism
Abstract Introduction: Acute myeloid leukemia (AML), which is characterized by an abnormal growth of myeloid cells, is estimated to be the s...
Elderly Acute Myeloid Leukemia (AML) with NPM1 or FLT3-ITD mutated: Is venetoclax the game changer also in fit patients? a real-life retrospective analysis by the rete ematologica lombarda
Abstract Background. NPM1 and FLT3-ITD are the most frequently observed mutations in acute myeloid leukemia (AML). However, the intensity of...
Site-specific and latency - associated second primary malignancy in follicular lymphoma survivors : A SEER MP-SIR study (2000-2022)
Abstract Background Follicular lymphoma (FL), an indolent B-cell malignancy, has seen improved long-term survival since the introduction of...
A genome-wide CRISPR screen identifies conventional and novel ferroptosis regulators in Acute Myeloid Leukemia
Abstract Background: Acute myeloid leukemia (AML) often acquires drug resistance and relapses after standard apoptosis-based therapy. Ferrop...
Impact of iptacopan, a complement inhibitor, on Chinese patients with paroxysmal nocturnal hemoglobinuria: A multicenter retrospective cohort study
Abstract introduction: Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and life-threatening acquired hematopoietic stem cell disorder ch...
Incidence and risk factors for immune effector cell-associated neurotoxicity syndrome in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study
Abstract Introduction: Anti-CD19 chimeric antigen receptor T-cell (CART) therapy is feasible with an acceptable safety profile in older pati...
Therapy-induced senescence reprograms non-M3 AML into a drug-exploitable APL-like state
Abstract Cellular senescence is a dynamic cancer cell condition with both tumor-suppressive and relapse-promoting features. While terminatin...
Trends in cardiovascular mortality in Hodgkin and non-Hodgkin lymphoma: A nationwide analysis from 1999 to 2020
Abstract Background: Cardiovascular disease (CVD) is a leading cause of non-cancer-related death among cancer survivors, particularly those...
A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma
Abstract Introduction LBL-034 is a humanized IgG1 subtype asymmetric bispecific antibody targeting GPRC5D and CD3 with a 2:1 format. Its uni...
Frequency of and finding risk factors for thromboembolism and major bleeding in patients with myelodysplastic syndrome undergoing allogeneic transplantation
Abstract INTRO: The myelodysplastic syndromes (MDS) are a heterogenous group of neoplasms with dysregulation of hematopoiesis, increasing ri...
Impact of HLA-b leader matching status on prognosis and underlying mechanism in patients with hematological malignancies following haploidentical hematopoietic stem cell transplantation
Abstract Background Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) represents a pivotal therapeutic approach for the tr...
Enhanced IPSS-m: A comorbidity-integrated model for improved clinical risk stratification in myelodysplastic neoplasms
Abstract Background: The International Prognostic Scoring System–Molecular (IPSS-M) remains the benchmark for risk stratification in myelodys...
Resolving the debate: A systematic review and network meta-analysis of hydroxyurea vs. newer FDA-approved pharmacological therapies in sickle cell disease
Abstract Introduction: Sickle cell disease (SCD) is a debilitating genetic disorder characterized by vaso-occlusive crises, organ damage, an...
Trends in mortality from multiple myeloma and diabetes mellitus in the United States: A retrospective analysis from 1999 to 2020
Abstract Background: Diabetes mellitus has been associated with an increased risk of multiple myeloma. This has been supported by multiple e...
Use of population-scale multiomics to define the prothrombotic phenotype of Protein C deficiency
Abstract Background: Thrombosis patients are often evaluated for deficiency in protein C (PC, PROC), but the phenotype of PC deficiency rema...
Low levels of wilms tumor 1 (WT1) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia
Abstract INTRODUCTION: Mutations in the Wilms Tumor 1 (WT1) occur in 6-15% of Acute Myelogenous Leukemia (AML) cases, and is associated with...